Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up - Here's What Happened

Key Points

• Cullinan Therapeutics shares opened higher at $17.24, up from a previous close of $16.04, though they later traded near $16.30.
• HC Wainwright reiterated its Buy rating, raised several earnings forecasts and projected a return to quarterly profitability in Q4 2027. Its $35 price target, alongside a consensus target of $33.71, implies significant upside.
• Despite favorable analyst sentiment, Cullinan remains a clinical-stage biotechnology company expected to post substantial losses through 2026 and 2027; its latest quarterly loss also narrowly missed estimates.

Shares of Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) gapped up before the market opened on Tuesday. The stock had previously closed at $16.04, but opened at $17.24. Cullinan Therapeutics shares last traded at $16.2950, with a volume of 225,289 shares trading hands.

More Cullinan Therapeutics News

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple EPS forecasts and reiterated its Buy rating. The firm increased its Q3 2026 estimate to a loss of $0.86 per share from $0.90, Q4 2026 to a loss of $0.89 from $0.93, and FY2026 to a loss of $3.45 from $3.53. It also lifted estimates for Q1-Q3 2027 and sharply improved its FY2027 forecast to a loss of $1.81 per share from $3.89. HC Wainwright Has Optimistic Opinion of CGEM Q3 Earnings
• Positive Sentiment: The most notable change was a projected return to quarterly profitability. HC Wainwright now expects CGEM to earn $0.39 per share in Q4 2027, compared with its previous forecast for a $1.00 loss, suggesting improved operating performance and a potentially faster path toward profitability.
• Positive Sentiment: The analyst’s $35 price target implies substantial upside from recent trading levels, reinforcing the view that Cullinan’s drug-development pipeline could create significant long-term value.
• Neutral Sentiment: Despite the upgrades, Cullinan is still expected to report substantial losses through most of 2026 and 2027. The company remains a development-stage biotechnology business, so future results will depend heavily on clinical progress, regulatory milestones and funding needs.
• Negative Sentiment: HC Wainwright’s FY2026 loss estimate of $3.45 per share remains worse than the broader consensus estimate of a $3.08 loss, indicating that near-term earnings expectations are not uniformly favorable.

Analysts Set New Price Targets

CGEM has been the subject of a number of analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. Wall Street Zen lowered Cullinan Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, September 13th. BTIG Research restated a "buy" rating and set a $40.00 price objective on shares of Cullinan Therapeutics in a research note on Friday, September 25th. HC Wainwright reaffirmed a "buy" rating and set a $35.00 price objective on shares of Cullinan Therapeutics in a research report on Friday. Finally, TD Cowen upgraded Cullinan Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $33.71.

Cullinan Therapeutics Price Performance

The stock has a fifty day moving average of $19.50 and a 200 day moving average of $16.76. The stock has a market cap of $1.13 billion, a price-to-earnings ratio of -5.63 and a beta of -0.05.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.01). As a group, equities analysts expect that Cullinan Therapeutics, Inc. will post -3.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Cullinan Therapeutics

In related news, insider Jennifer Michaelson sold 30,000 shares of the business's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $20.26, for a total value of $607,800.00. Following the completion of the transaction, the insider directly owned 162,844 shares in the company, valued at $3,299,219.44. The trade was a 15.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 8.60% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC acquired a new stake in shares of Cullinan Therapeutics during the 2nd quarter valued at about $25,000. Allworth Financial LP purchased a new position in shares of Cullinan Therapeutics during the 2nd quarter valued at approximately $53,000. Quantbot Technologies LP acquired a new stake in Cullinan Therapeutics in the 2nd quarter valued at $53,000. Seven Fleet Capital Management LP acquired a new stake in Cullinan Therapeutics in the 4th quarter valued at $31,000. Finally, Royal Bank of Canada increased its holdings in Cullinan Therapeutics by 160.6% in the 1st quarter. Royal Bank of Canada now owns 4,044 shares of the company's stock worth $58,000 after acquiring an additional 2,492 shares in the last quarter. Hedge funds and other institutional investors own 86.31% of the company's stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and autoimmune diseases. The company uses a portfolio-based approach to advance targeted therapies and immune-modulating treatments intended to address significant unmet medical needs.

Cullinan's pipeline includes zovoltamab brengitecan (CLN-978), an investigational CD19-directed T-cell engager being studied in B-cell malignancies and autoimmune conditions, and CLN-619, an investigational antibody designed to target MICA and MICB proteins and stimulate anti-tumor immune responses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.